MARKET COMPOSITE
Market TodayThemes and Stocks SummaryThematic Stock SearchCrypto SummaryFAQAbout
BBIO - BridgeBio Pharma Inc
$8.95
-0.16(-1.76%)9:00:00 PM 1/30/2023
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 20 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include BBP-265, an oral small molecule transthyretin (TTR), which is ongoing Phase 3 clinical trial for the treatment of TTR amyloidosis, including cardiomyopathy and polyneuropathy manifestations; infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor for the treatment of FGFR-driven cancers and achondroplasia; BBP-631, a preclinical adeno-associated virus gene transfer product candidate for the treatment of congenital adrenal hyperplasia caused by 21OHD; and BBP-454, a preclinical development program for small molecule inhibitors of KRAS for the treatment of pan-mutant KRAS-driven cancers. The company also engages in developing products for Mendelian, genetic dermatology, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license agreements with the Leland Stanford Junior University, The Regents of the University of California, and Leidos Biomedical Research, Inc.; strategic collaboration agreements with Johns Hopkins University and University of Florida; collaboration with University of Colorado Anschutz Medical Campus to advance novel research on genetically driven diseases into therapeutic applications for patients; collaboration with Salk Institute for Biological Studies; and Maze Therapeutics establishes a joint venture, Contour Therapeutics to advance precision medicine to treat cardiovascular diseases. The company was founded in 2015 and is headquartered in Palo Alto, California.
Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Summary:

  • MACD is crossing MACD signal line at 0.1. MACD crossing signal line is bullish signal.
Stock Statistics
MarketCap1.3B
PE Ratio-2.7
PEG Ratio0.2
P/B15.7
P/S (ttm)1051.0
Earning Growth (QoQ)
Revenue Growth (QoQ)
Short %13%
Held by Institutions %95%
1 Day Vol Adjusted Return-0.3
1 Month Vol Adjusted Return6.2
3 Month Vol Adjusted Return-2.6
6 Month Vol Adjusted Return0.5
20 Days SMA Price ZScore1.0
50 Days SMA Price ZScore0.5
12 -26 Days PPO2.0
1 Month Average Short Volume Ratio44.3
1 Day Volume Change ZScore-1.5
1 Month Daily Vol5.3
Related Topics
Peers

Related Peers

Stock news